SNSmith & Nephew SNN · NYSE
$30.11 -1.18% (-$0.36)
- Market cap
- $12.6B
- Enterprise value
- $15.7B
- P/E
- 19.9x
- Forward P/E
- 13.2x
- PEG
- 0.4x
- P/S
- 2.0x
- P/FCF
- 14.8x
- EV/EBITDA
- 11.3x
- ROIC
- 6.8%
- Gross margin
- 68.4%
- Net margin
- 10.1%
- Dividend yield
- 2.64%
- Payout ratio
- 52.4%
- Net debt/EBITDA
- 2.2x
- Beta
- 0.69
- Free float
- 99.0%
About the company
Smith & Nephew plc (SN) is a British company specializing in the manufacture and distribution of healthcare devices and surgical products. Their portfolio includes a wide range of products in the fields of orthopedics, sports medicine, joint surgery, traumatology, and advanced surgical technologies. The company manufactures and supplies implants, prosthetics, instruments, and devices for orthopedic surgeries, as well as products for wound care, skin care, and other surgical needs. Smith & Nephew focuses on providing innovative and high-quality products that help physicians achieve better outcomes for their patients. The company also invests in research and development of new technologies and products to continuously innovate and improve its portfolio. Smith & Nephew plc (SN) shares may be attractive to investors seeking investments in companies operating in the healthcare devices sector with a wide range of products and an emphasis on innovation and quality.
Sector
Healthcare
Industry
Medical - Devices
CEO
Deepak S. Nath
Employees
18,362
Headquarters
Watford
Valuation
Is today's price reasonable?
- What to watch: The share price is above the Bulios Fair Price.
Growth and estimates
Is it growing, and what comes next?
- What speaks for it: Earnings per share grew by 42% a year over the last 3 years.
- What to watch: It missed profit estimates 6 times in the last 8 quarters.
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
- What speaks for it: Out of every 100 USD of revenue, 14 USD is left as free cash.
Financial health
Can it carry its debt?
Capital and dividends
What does the company do with the money it earns?
- What speaks for it: It bought back its own shares for $503.2M in the last fiscal year, 4.0% of its market value.
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number